Marsh & McLennan Cos (NYSE:MMC) Azioni

MARSH & MCLENNAN COS

Marsh & McLennan

Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.

Marsh &amp; McLennan Cos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) short percent of float has risen 5.74% since its last report. The company recently reported that it has 6.34 million shares sold short, which is 1.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.23 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Marsh &amp; McLennan Cos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752170421_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Marsh &amp; McLennan Cos has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Marsh &amp; McLennan Cos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Marsh &amp; McLennan Cos's peer group average for short interest as a percentage of float is 3.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About Marsh & McLennan Cos?

Wells Fargo analyst Elyse Greenspan maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Equal-Weight and raises the price target from $228 to $229.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Marsh & McLennan Cos, Raises Price Target to $229

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Underperform and lowers the price target from $215 to $214.

Keefe, Bruyette & Woods Maintains Underperform on Marsh & McLennan Cos, Lowers Price Target to $214

The Board of Directors of Marsh McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) today declared a 10% increase in the quarterly dividend from $0.815 to $0.900 per share on outstanding common stock, payable on August 15, 2025, to stockholders of record on July 24, 2025.

Dividends

Marsh McLennan Increase Quarterly Dividend From $0.815 To $0.90 Per Share

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 2.78% on an annualized basis producing an average annual return of 14.26%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $106.91 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 10 years ago, it would be worth $3,791.86 today based on a price of $216.97 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751063412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Marsh & McLennan Cos Stock In The Last 10 Years

Marsh McLennan's Oliver Wyman To Acquire Validate Health; No Terms Disclosed

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 15 years by 3.87% on an annualized basis producing an average annual return of 15.96%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $105.60 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 15 years ago, it would be worth $935.49 today based on a price of $214.32 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750343415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Marsh & McLennan Cos 15 Years Ago Would Be Worth Today

WIIM

Shares of auto-insurance companies are trading lower after a Goldman Sachs note indicated that insurance costs are projected to decline due to disruptions from self-driving cars, which may result in fewer accidents and shifting risks.

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 3.97% on an annualized basis producing an average annual return of 14.8%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $114.08 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 10 years ago, it would be worth $3,980.91 today based on a price of $231.53 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748384110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Marsh & McLennan Cos 10 Years Ago Would Be Worth This Much Today

In the current session, the stock is trading at $229.22, after a 0.33% increase. Over the past month, Marsh &amp; McLennan Cos Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) stock increased by 4.55%, and in the past year, by 12.38%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1748012423_0.png" alt="Past Year Chart" />

<h3>Comparing Marsh &amp; McLennan Cos P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 56.57 in the Insurance industry, Marsh &amp; McLennan Cos Inc. has a lower P/E ratio of 28.03. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748012423_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Marsh & McLennan Cos

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.64% on an annualized basis producing an average annual return of 14.78%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.92 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,844.79 today based on a price of $227.13 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746631889_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth Today

Marsh &amp; McLennan Cos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) short percent of float has risen 13.33% since its last report. The company recently reported that it has 4.99 million shares sold short, which is 1.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Marsh &amp; McLennan Cos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746453626_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Marsh &amp; McLennan Cos has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Marsh &amp; McLennan Cos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Marsh &amp; McLennan Cos's peer group average for short interest as a percentage of float is 2.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Marsh & McLennan Cos's Recent Short Interest

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.5% on an annualized basis producing an average annual return of 14.72%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.99 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,188.11 today based on a price of $227.29 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746226815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth This Much Today

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Underperform and lowers the price target from $220 to $215.

Keefe, Bruyette & Woods Maintains Underperform on Marsh & McLennan Cos, Lowers Price Target to $215

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.83% on an annualized basis producing an average annual return of 14.73%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $108.47 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 20 years ago, it would be worth $1,560.78 today based on a price of $220.07 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745019912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled positive <a href="https://www.benzinga.com/topic/donald-trump">momentum in trade negotiations.</a>
Speaking ahead of a scheduled meeting with Italian Prime Minister Giorgia Meloni, Trump expressed strong confidence in reaching a trade agreement with the European Union. He also hinted at progress with China, stating, "We will make a good deal with China." 
Meanwhile, U.S. Treasury Secretary Scott Bessent noted that trade talks with Japan are moving in a highly satisfactory direction.
By midday in New York, the S&amp;P 500 had climbed 0.9%, while the Nasdaq 100 gained 0.5%, recouping some losses after a 3% slide on Wednesday. The Dow Jones, however, slipped 0.9%, weighed down by a sharp 23% plunge in UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) after the company slashed its full-year earnings forecast.
Energy stocks led the day&#8217;s gains, buoyed by rising oil prices. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) rallied 4.1%, while Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) advanced 3.5%.
Gold prices retreated nearly 1% after a strong multi-day rally, pressured by a firmer U.S. dollar and rising Treasury yields. The 10-year Treasury yield climbed six basis points to 4.34%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged up 0.9% to $85,000.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg (%)</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,884.35</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,323.43</td>
<td>0.9%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,357.77</td>
<td>0.5%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,441.72</td>
<td colspan="2">-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.8% to $530.09.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 0.7% to $394.05.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.5% to $446.19.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 1% to $186.67.</li>
<li>The&nbsp;Energt&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 3.5%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.1%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Eli Lilly Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) surged 16% after announcing that its oral GLP-1 receptor agonist, Orforglipron, successfully completed Phase 3 trials without requiring food or water restrictions.</li>
<li>Fidelity National Information Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) jumped 9% after announcing a $13.5 billion deal to acquire Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)&#8217;s Issuer Solutions business. The move is aimed at bolstering FIS's fintech capabilities and is expected to generate over $125 million in annual revenue synergies. Shares of GPN tumbled 15%. </li>
<li>Companies reacting to earnings reports included American Express Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), up 0.5%; Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), up 1.9%; Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), up 2.7%; Marsh &amp; McLennan Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) down 3.3%; Truist Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>), up 1.3%; State Street Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>), up 3.2%; KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>), up 3.7% and Huntington Bancshares Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>), up 4%.</li>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) rose 2% ahead of the earnings report, which is slated for release after the market close. </li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Economics

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

HBAN

NFLX

SCHW

Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What's Driving Markets Thursday?

Marsh & McLennan shares are trading lower after the company reported worse-than-expected Q1 revenue results.

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) reported quarterly earnings of $3.06 per share which beat the analyst consensus estimate of $3.02 by 1.32 percent. This is a 4.79 percent increase over earnings of $2.92 per share from the same period last year. The company reported quarterly sales of $7.06 billion which missed the analyst consensus estimate of $7.08 billion by 0.31 percent. This is a 9.08 percent increase over sales of $6.47 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Marsh & McLennan Q1 Adj EPS $3.06 Beats $3.02 Estimate, Sales $7.06B Miss $7.08B Estimate

<h3>Companies Reporting Before The Bell</h3>
• Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $250.69 million. 
• Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $23.92 billion. 
• Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) is expected to report quarterly earnings at $1.05 per share on revenue of $220.76 million. 
• Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) is estimated to report quarterly earnings at $1.01 per share on revenue of $5.54 billion. 
• Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) is estimated to report quarterly earnings at $0.42 per share on revenue of $1.97 billion. 
• ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $3.96 billion. 
• State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) is likely to report quarterly earnings at $2.01 per share on revenue of $3.32 billion. 
• American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) is expected to report quarterly earnings at $3.47 per share on revenue of $16.93 billion. 
• Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) is estimated to report quarterly earnings at $3.00 per share on revenue of $7.08 billion. 
• D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) is estimated to report quarterly earnings at $2.65 per share on revenue of $8.03 billion. 
• Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) is projected to report quarterly earnings at $4.82 per share on revenue of $1.21 billion. 
• Forestar Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>) is likely to report quarterly earnings at $0.73 per share on revenue of $363.15 million. 
• Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $2.16 billion. 
• Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) is estimated to report quarterly earnings at $0.95 per share on revenue of $283.30 million. 
• Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $1.83 billion. 
• Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) is likely to report quarterly earnings at $1.06 per share on revenue of $2.68 billion. 
• Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) is expected to report quarterly earnings at $0.87 per share on revenue of $4.94 billion. 
• UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is likely to report quarterly earnings at $7.29 per share on revenue of $111.60 billion. 
• Insteel Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $149.85 million. 
• Hooker Furnishings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFT#NASDAQ">HOFT</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $101.16 million. 
• Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) is estimated to report quarterly earnings at $0.31 per share on revenue of $1.89 billion. 
• Infosys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $4.90 billion. 
• KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $1.75 billion. 
<h3>Companies Reporting After The Bell</h3>
• Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is expected to report quarterly earnings at $5.72 per share on revenue of $10.51 billion. 
• Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDB#NASDAQ">INDB</a>) is expected to report quarterly earnings at $1.16 per share on revenue of $175.04 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLY

FITB

HOFT

IIIN

INDB

INFY

TCBI

Earnings Scheduled For April 17, 2025

In the current session, the stock is trading at $233.91, after a 0.67% increase. Over the past month, Marsh &amp; McLennan Cos Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) stock increased by 1.03%, and in the past year, by 16.47%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1744819229_0.png" alt="Past Year Chart" />

<h3>Evaluating Marsh &amp; McLennan Cos P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 62.22 in the Insurance industry, Marsh &amp; McLennan Cos Inc. has a lower P/E ratio of 28.41. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744819229_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Press Releases

Marsh McLennan's Mercer Completes Acquisition of SECOR Asset Management

Employers face rising healthcare costs from climate risks and new forecasting tool helps them assess the impact

Insurance

GI Partners Teams with Industry Veterans Brad Emmons and Brian Hanuschak to Launch Tech-Enabled MGA Platform

Oliver Wyman Unveils Comprehensive Labor Cost Per Vehicle Analysis Amidst Changing Automotive Landscape

Marsh McLennan Stockholders Re-Elect Board of Directors During 2025 Meeting

Marsh McLennan to Host Second Quarter Earnings Investor Call on July 17

Marsh McLennan's Oliver Wyman to Acquire Healthcare Analytics Business Validate Health

Marsh McLennan Agency Acquires Excel Insurance

Marsh McLennan Increases Quarterly Cash Dividend

Marsh McLennan Appoints Bruce Broussard to its Board of Directors

Abacus Global Management, Inc. - Class A Common Stock

Abacus Global Management

AIFU

Arthur J. Gallagher

Aon plc Class A Ordinary Shares (Ireland)

Brown & Brown

The Baldwin Insurance Group, Inc. - Class A Common Stock

Baldwin Insurance

Cheche Group Inc. - Class A Ordinary Shares

Cheche Group

Crawford & Company Common Stock

eHealth

GoHealth

Goosehead Insurance, Inc. - Class A Common Stock

Goosehead Insurance

Hagerty

Hippo Holdings

Health In Tech, Inc. - Class A Common Stock

Health In Tech

Huize Holding Limited - American Depositary Shares

Huize Holding

Marsh & McLennan Companies, Inc. Common Stock

Marsh & McLennan Cos

Ryan Specialty Holdings, Inc. Class A Common Stock

Ryan Specialty Hldgs

SelectQuote

TIAN RUIXIANG Holdings Ltd - Class A Ordinary Shares

Tian Ruixiang Holdings

TWFG

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Comments

Marsh & McLennan Cos

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO